HAIC Plus PD-1 Antibody vs HAIC Plus Sorafenib for Advanced HCC
Status:
Withdrawn
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of hepatic artery infusion
chemotherapy (HAIC) combined with Programmed Cell Death Protein-1 (PD-1) antibody compared
with HAIC plus sorafenib in patients with advanced hepatocellular carcinoma (HCC)
Phase:
Phase 2
Details
Lead Sponsor:
Sun Yat-sen University
Collaborators:
Guangzhou No.12 People's Hospital Kaiping Central Hospital